JP2015523962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523962A5 JP2015523962A5 JP2015510445A JP2015510445A JP2015523962A5 JP 2015523962 A5 JP2015523962 A5 JP 2015523962A5 JP 2015510445 A JP2015510445 A JP 2015510445A JP 2015510445 A JP2015510445 A JP 2015510445A JP 2015523962 A5 JP2015523962 A5 JP 2015523962A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- amino acid
- fel
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims description 145
- 239000000427 antigen Substances 0.000 claims description 142
- 102000036639 antigens Human genes 0.000 claims description 142
- 108091007433 antigens Proteins 0.000 claims description 142
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 113
- 239000012634 fragment Substances 0.000 claims description 112
- 241000282326 Felis catus Species 0.000 claims description 103
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 239000000284 extract Substances 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 206010020751 Hypersensitivity Diseases 0.000 claims description 34
- 208000030961 allergic reaction Diseases 0.000 claims description 26
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 24
- 208000001840 Dandruff Diseases 0.000 claims description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 16
- 230000035945 sensitivity Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 4
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 4
- 230000001668 ameliorated effect Effects 0.000 claims description 4
- 229940125715 antihistaminic agent Drugs 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 229940124630 bronchodilator Drugs 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 239000000850 decongestant Substances 0.000 claims description 4
- 229940124581 decongestants Drugs 0.000 claims description 4
- 229960005139 epinephrine Drugs 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 229940023041 peptide vaccine Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000033399 Anaphylactic responses Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 2
- 241000282324 Felis Species 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642083P | 2012-05-03 | 2012-05-03 | |
| US61/642,083 | 2012-05-03 | ||
| US201261718044P | 2012-10-24 | 2012-10-24 | |
| US61/718,044 | 2012-10-24 | ||
| US201361783312P | 2013-03-14 | 2013-03-14 | |
| US61/783,312 | 2013-03-14 | ||
| PCT/US2013/039192 WO2013166236A1 (en) | 2012-05-03 | 2013-05-02 | Human antibodies to fel d1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017116808A Division JP6603269B2 (ja) | 2012-05-03 | 2017-06-14 | Ｆｅｌ ｄ１に対するヒト抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523962A JP2015523962A (ja) | 2015-08-20 |
| JP2015523962A5 true JP2015523962A5 (enExample) | 2016-06-16 |
| JP6400569B2 JP6400569B2 (ja) | 2018-10-03 |
Family
ID=48326501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510445A Active JP6400569B2 (ja) | 2012-05-03 | 2013-05-02 | Ｆｅｌｄ１に対するヒト抗体およびその使用方法 |
| JP2017116808A Active JP6603269B2 (ja) | 2012-05-03 | 2017-06-14 | Ｆｅｌ ｄ１に対するヒト抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017116808A Active JP6603269B2 (ja) | 2012-05-03 | 2017-06-14 | Ｆｅｌ ｄ１に対するヒト抗体およびその使用方法 |
Country Status (33)
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| EP2564695B1 (en) | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
| CN103945689B (zh) | 2011-09-19 | 2016-10-19 | 科马布有限公司 | 免疫球蛋白基因多样性的操纵及多抗体治疗剂 |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| CA2922113C (en) | 2013-08-23 | 2023-05-23 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| AU2014330922A1 (en) | 2013-10-01 | 2016-03-03 | Kymab Limited | Animal models and therapeutic molecules |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| PT3221359T (pt) | 2014-11-17 | 2020-06-23 | Regeneron Pharma | Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20 |
| JP6773679B2 (ja) | 2015-03-30 | 2020-10-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域 |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| WO2017042241A1 (en) * | 2015-09-08 | 2017-03-16 | Universität Zürich | Compositions against cat allergy |
| MX393066B (es) | 2016-04-18 | 2025-03-24 | Celldex Therapeutics Inc | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| WO2018118713A1 (en) * | 2016-12-22 | 2018-06-28 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| US10774137B2 (en) | 2017-01-24 | 2020-09-15 | Société des Produits Nestlé S.A. | Compositions and methods for reducing at least one symptom of human allergy to cats |
| AU2018298039B2 (en) | 2017-07-06 | 2023-02-02 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
| SG11202004380QA (en) | 2017-12-22 | 2020-06-29 | Regeneron Pharma | System and method for characterizing drug product impurities |
| CN111655722A (zh) | 2018-01-31 | 2020-09-11 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| BR112020013426A2 (pt) | 2018-02-28 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| EA202092203A1 (ru) | 2018-03-19 | 2020-12-07 | Ридженерон Фармасьютикалз, Инк. | Способы анализа и реагенты для микрочипового капиллярного электрофореза |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CN112166119B (zh) * | 2018-05-18 | 2024-12-20 | 陈扎克伯格生物中心旧金山公司 | 从人中分离过敏原特异性抗体的方法及其用途 |
| EA202092684A1 (ru) | 2018-08-27 | 2021-03-11 | Ридженерон Фармасьютикалз, Инк. | Применение рамановской спектроскопии для последующей очистки |
| TWI866924B (zh) | 2018-08-30 | 2024-12-21 | 美商再生元醫藥公司 | 用於將蛋白質複合物定特徵之方法 |
| CN117110492A (zh) | 2019-01-16 | 2023-11-24 | 瑞泽恩制药公司 | 鉴别蛋白质中的游离巯基的方法 |
| SG11202110911RA (en) | 2019-05-13 | 2021-10-28 | Regeneron Pharma | Improved competitive ligand binding assays |
| BR112022004885A2 (pt) | 2019-09-24 | 2022-06-07 | Regeneron Pharma | Sistemas e métodos para uso e regeneração de cromatografia |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| IL293112A (en) | 2019-11-25 | 2022-07-01 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
| BR112022014212B1 (pt) | 2020-01-21 | 2024-01-23 | Regeneron Pharmaceuticals, Inc | Métodos de análise de uma amostra incluindo uma proteína de interesse |
| EP4204449A1 (en) | 2020-08-26 | 2023-07-05 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| KR20230058094A (ko) | 2020-08-31 | 2023-05-02 | 리제너론 파아마슈티컬스, 인크. | 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략 |
| WO2022115588A1 (en) | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| US12350374B2 (en) | 2020-12-17 | 2025-07-08 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| JP2024503408A (ja) | 2021-01-20 | 2024-01-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞培養におけるタンパク質力価の改善方法 |
| JP2024512299A (ja) | 2021-03-03 | 2024-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質の粘度を定量及び変更するためのシステム及び方法 |
| CA3213283A1 (en) | 2021-03-11 | 2022-09-15 | IgGenix, Inc. | Methods and systems for predicting allergic response |
| US20220309215A1 (en) | 2021-03-26 | 2022-09-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| CA3220848A1 (en) | 2021-06-01 | 2022-12-08 | Timothy Riehlman | Microchip capillary electrophoresis assays and reagents |
| US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
| CN118139881A (zh) | 2021-09-20 | 2024-06-04 | 瑞泽恩制药公司 | 控制抗体异质性的方法 |
| IL311248A (en) | 2021-10-07 | 2024-05-01 | Regeneron Pharma | PH meter calibration and repair |
| TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ｐｈ建模及控制之系統及方法 |
| TW202330104A (zh) | 2021-10-26 | 2023-08-01 | 美商再生元醫藥公司 | 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法 |
| CN114113278B (zh) * | 2021-11-24 | 2024-08-02 | 中国计量科学研究院 | 一种基于质谱的体外诊断试剂抗体的表位定位方法 |
| US20230174632A1 (en) * | 2021-12-08 | 2023-06-08 | IgGenix, Inc. | Combinations for allergy therapy |
| EP4493921A1 (en) | 2022-03-18 | 2025-01-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| CA3251374A1 (en) | 2022-06-23 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | METHODS FOR IDENTIFYING AND EVALUATING GENETIC SIGNATURES OF CAT ALLERGY IN A SUBJECT BY DETERMINING A STRATIFIED SCORE BASED ON GENE EXPRESSION. |
| EP4634659A1 (en) | 2022-12-16 | 2025-10-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2024158880A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| EP4655595A1 (en) | 2023-01-25 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| IL322811A (en) | 2023-03-01 | 2025-10-01 | Regeneron Pharma | Anti-FEL D1 antibody formulations |
| WO2024200854A1 (en) | 2023-03-31 | 2024-10-03 | Alk-Abelló A/S | Allergen binding antibodies suitable for treating tree pollen allergies |
| AU2024265540A1 (en) | 2023-05-01 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| CN117004650B (zh) * | 2023-06-25 | 2024-05-14 | 山东立菲生物产业有限公司 | 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用 |
| TW202528736A (zh) | 2023-09-08 | 2025-07-16 | 美商再生元醫藥公司 | 用於評估層析管柱完整性的方法及系統 |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| TW202532098A (zh) | 2023-09-29 | 2025-08-16 | 美商再生元醫藥公司 | 使用控制成核之冷凍乾燥 |
| CN117069865B (zh) * | 2023-10-12 | 2024-03-01 | 中国农业科学院饲料研究所 | 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| TW202535934A (zh) | 2023-11-02 | 2025-09-16 | 美商再生元醫藥公司 | 利用應力來降低脂酶活性的方法 |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| CN117964767B (zh) * | 2024-03-29 | 2024-08-06 | 北京恩泽康泰生物科技有限公司 | 抗rage抗体、细胞外囊泡及其制备方法和应用 |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512283A (en) | 1990-07-06 | 1996-04-30 | Allergene, Inc. | Methods for the selective suppression of an immune response to dust mite der Pi |
| WO1993013772A1 (en) | 1992-01-21 | 1993-07-22 | Immulogic Pharmaceutical Corporation | Methods for using histamine derivatives as immunomodulators and in immunotherapeutics |
| EP0675734A4 (en) | 1992-12-21 | 1997-05-07 | Tanox Biosystems Inc | MONOCLONAL ALLERGEN-SPECIFIC IgA ANTIBODIES AND RELATED PRODUCTS FOR THE TREATMENT OF ALLERGIES. |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| NZ561040A (en) * | 2005-03-18 | 2009-04-30 | Cytos Biotechnology Ag | Cat allergen fusion proteins and use thereof |
| US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
| GB0513878D0 (en) * | 2005-07-06 | 2005-08-10 | Mars Inc | Cat allergen |
| WO2007065633A1 (en) * | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
| WO2007113633A2 (en) * | 2006-04-03 | 2007-10-11 | Pfizer Products Inc. | Immunogenic compositions comprising cat allergen fel dl |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| AT503690A1 (de) * | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP1921142A1 (en) * | 2006-11-07 | 2008-05-14 | Cytos Biotechnology AG | Selection of human monoclonal antibodies by eukaryotic cell display |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| AU2008234248C1 (en) * | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| CA2688275A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| HUE034431T2 (en) * | 2007-07-09 | 2018-02-28 | Nestec Sa | Procedures to reduce allergies caused by environmental allergens |
| MY161564A (en) | 2007-08-10 | 2017-04-28 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| AU2011312191B2 (en) | 2010-10-06 | 2015-07-02 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| CA2922113C (en) | 2013-08-23 | 2023-05-23 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| WO2018118713A1 (en) | 2016-12-22 | 2018-06-28 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
-
2013
- 2013-05-01 JO JOP/2013/0131A patent/JO3820B1/ar active
- 2013-05-02 SM SM20250396T patent/SMT202500396T1/it unknown
- 2013-05-02 BR BR122019023685-2A patent/BR122019023685B1/pt active IP Right Grant
- 2013-05-02 KR KR1020147033137A patent/KR102185516B1/ko active Active
- 2013-05-02 LT LTEP21194412.9T patent/LT3978522T/lt unknown
- 2013-05-02 SI SI201332111T patent/SI3978522T1/sl unknown
- 2013-05-02 MX MX2014013371A patent/MX377634B/es active IP Right Grant
- 2013-05-02 RU RU2014148502A patent/RU2658491C2/ru active
- 2013-05-02 BR BR112014026852-5A patent/BR112014026852B1/pt active IP Right Grant
- 2013-05-02 EP EP19218187.3A patent/EP3660047B1/en active Active
- 2013-05-02 ES ES13721544T patent/ES2780392T3/es active Active
- 2013-05-02 DK DK13721544.8T patent/DK2844672T3/da active
- 2013-05-02 LT LTEP13721544.8T patent/LT2844672T/lt unknown
- 2013-05-02 IN IN8767DEN2014 patent/IN2014DN08767A/en unknown
- 2013-05-02 SM SM20200241T patent/SMT202000241T1/it unknown
- 2013-05-02 AR ARP130101494 patent/AR090914A1/es unknown
- 2013-05-02 ES ES21194412T patent/ES3049982T3/es active Active
- 2013-05-02 RS RS20211475A patent/RS62636B1/sr unknown
- 2013-05-02 SG SG10201608378UA patent/SG10201608378UA/en unknown
- 2013-05-02 MY MYPI2020006733A patent/MY195564A/en unknown
- 2013-05-02 EP EP21194412.9A patent/EP3978522B1/en active Active
- 2013-05-02 PT PT137215448T patent/PT2844672T/pt unknown
- 2013-05-02 TW TW106119738A patent/TW201803901A/zh unknown
- 2013-05-02 HR HRP20200652TT patent/HRP20200652T1/hr unknown
- 2013-05-02 RS RS20200539A patent/RS60282B1/sr unknown
- 2013-05-02 TW TW102115645A patent/TWI644921B/zh active
- 2013-05-02 EP EP25194366.8A patent/EP4653056A2/en active Pending
- 2013-05-02 WO PCT/US2013/039192 patent/WO2013166236A1/en not_active Ceased
- 2013-05-02 ES ES19218187T patent/ES2898372T3/es active Active
- 2013-05-02 MY MYPI2014002857A patent/MY164101A/en unknown
- 2013-05-02 CA CA2871077A patent/CA2871077C/en active Active
- 2013-05-02 HU HUE19218187A patent/HUE057062T2/hu unknown
- 2013-05-02 CN CN201380035000.9A patent/CN104411719B/zh active Active
- 2013-05-02 SM SM20220014T patent/SMT202200014T1/it unknown
- 2013-05-02 NZ NZ701124A patent/NZ701124A/en unknown
- 2013-05-02 MY MYPI2017701565A patent/MY181422A/en unknown
- 2013-05-02 DK DK21194412.9T patent/DK3978522T3/da active
- 2013-05-02 JP JP2015510445A patent/JP6400569B2/ja active Active
- 2013-05-02 PT PT211944129T patent/PT3978522T/pt unknown
- 2013-05-02 US US13/875,401 patent/US9079948B2/en active Active
- 2013-05-02 CN CN201910294004.8A patent/CN110240651B/zh active Active
- 2013-05-02 HU HUE13721544A patent/HUE049440T2/hu unknown
- 2013-05-02 SI SI201331698T patent/SI2844672T1/sl unknown
- 2013-05-02 PL PL19218187T patent/PL3660047T3/pl unknown
- 2013-05-02 PT PT192181873T patent/PT3660047T/pt unknown
- 2013-05-02 HR HRP20211932TT patent/HRP20211932T1/hr unknown
- 2013-05-02 SG SG10202102919XA patent/SG10202102919XA/en unknown
- 2013-05-02 PL PL13721544T patent/PL2844672T3/pl unknown
- 2013-05-02 EP EP13721544.8A patent/EP2844672B1/en active Active
- 2013-05-02 LT LTEP19218187.3T patent/LT3660047T/lt unknown
- 2013-05-02 NZ NZ733480A patent/NZ733480A/en unknown
- 2013-05-02 SG SG11201406748QA patent/SG11201406748QA/en unknown
- 2013-05-02 AU AU2013256251A patent/AU2013256251C1/en active Active
- 2013-05-02 FI FIEP21194412.9T patent/FI3978522T3/fi active
- 2013-05-02 SI SI201331935T patent/SI3660047T1/sl unknown
- 2013-05-03 UY UY34782A patent/UY34782A/es active IP Right Grant
-
2014
- 2014-10-08 ZA ZA2014/07302A patent/ZA201407302B/en unknown
- 2014-10-19 IL IL235121A patent/IL235121B/en active IP Right Grant
- 2014-11-03 MX MX2020003864A patent/MX2020003864A/es unknown
-
2015
- 2015-06-05 US US14/732,578 patent/US9475869B2/en active Active
-
2016
- 2016-09-13 US US15/263,848 patent/US10047152B2/en active Active
-
2017
- 2017-01-26 US US15/416,176 patent/US10047153B2/en active Active
- 2017-06-14 JP JP2017116808A patent/JP6603269B2/ja active Active
-
2018
- 2018-05-03 AU AU2018203087A patent/AU2018203087B9/en active Active
- 2018-07-05 US US16/028,275 patent/US11174305B2/en active Active
-
2020
- 2020-05-04 CY CY20201100408T patent/CY1124023T1/el unknown
- 2020-08-25 ZA ZA2020/05273A patent/ZA202005273B/en unknown
-
2021
- 2021-10-13 US US17/500,418 patent/US12252530B2/en active Active
- 2021-12-20 CY CY20211101115T patent/CY1124819T1/el unknown
-
2022
- 2022-03-09 ZA ZA2022/02846A patent/ZA202202846B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523962A5 (enExample) | ||
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP7458453B2 (ja) | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 | |
| KR102307248B1 (ko) | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 | |
| KR102492826B1 (ko) | Il-4r 억제제를 투여함으로써 알레르기 치료 및 알레르겐 특이적 면역요법을 강화시키는 방법 | |
| JP2020523004A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| JP2019531273A5 (enExample) | ||
| JP2021112207A5 (enExample) | ||
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JPWO2019175217A5 (enExample) | ||
| JPWO2019175220A5 (enExample) | ||
| JP2006528626A5 (enExample) | ||
| JPWO2019175226A5 (enExample) | ||
| JPWO2020191346A5 (enExample) | ||
| US20250034272A1 (en) | Compositions and methods for treating severe asthma | |
| JP2020531003A5 (enExample) | ||
| JPWO2020041537A5 (enExample) | ||
| JPWO2020163353A5 (enExample) | ||
| RU2021128133A (ru) | Введение ингибиторов pd-1 для лечения рака кожи | |
| TH61315B (th) | แอนติบอดีที่สมบูรณ์ของมนุษย์ต่อ 4-1bb ของมนุษย์ |